Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Rating of “Moderate Buy” from Analysts

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has received a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $87.3750.

Several brokerages have recently commented on KNSA. Citigroup increased their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Canaccord Genuity Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Wedbush raised their target price on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA opened at $78.08 on Monday. The stock has a market cap of $6.09 billion, a price-to-earnings ratio of 80.49 and a beta of 0.05. The business has a 50 day simple moving average of $69.89 and a 200 day simple moving average of $56.24. Kiniksa Pharmaceuticals International has a 52 week low of $33.25 and a 52 week high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30. The firm had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. On average, analysts predict that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current year.

Insider Activity

In other news, Director G Bradley Cole sold 3,673 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. This represents a 23.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 51.98% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its position in shares of Kiniksa Pharmaceuticals International by 6,384.0% in the second quarter. California State Teachers Retirement System now owns 2,721,648 shares of the company’s stock valued at $174,049,000 after purchasing an additional 2,679,673 shares during the period. Qube Research & Technologies Ltd boosted its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares during the period. Rubric Capital Management LP boosted its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after buying an additional 526,567 shares during the period. Bank of America Corp DE grew its stake in Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after buying an additional 506,576 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in Kiniksa Pharmaceuticals International by 213.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after buying an additional 447,536 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.